FDA-cleared profile

MammoScreen® (3)

Therapixel · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.

Clinical role
Concurrent reading and reporting support that supplies finding marks, suspicion scores, lesion type and location, reporting-system content, and optional patient-management-worklist content while the interpreting physician remains the sole decision-maker.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Use requires compatible FFDM/DBT systems and only the packet's supported current/prior combinations. Outputs are complementary information, not a replacement for physician review or judgment, and patient-management decisions must not rely on the analysis alone. Standalone testing used 100% Hologic exams from three US centers, so that cohort does not establish all vendors or local configurations.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible current FFDM, DBT+FFDM, or DBT+2DSM examinations, with optional compatible prior FFDM or DBT+2DSM examination acquired 6 to 60 months before the current study; the packet specifies supported current/prior combinations.
  • Who uses it?Intended users: Physicians qualified to read mammograms; the FDA reader study used MQSA-qualified and ABR-certified radiologists.
  • What does the software produce?Output: Graphical marks for soft-tissue lesions or calcifications, a MammoScreen Score from 1 to 10 at finding, breast, and case levels, lesion characterization as mass/asymmetry, distortion, or calcifications, and location including quadrant, depth, and distance from the nipple; outputs can support DICOM viewing, preliminary reporting, and worklist content.
  • What is its most important limitation?Key limitation: Use requires compatible FFDM/DBT systems and only the packet's supported current/prior combinations. Outputs are complementary information, not a replacement for physician review or judgment, and patient-management decisions must not rely on the analysis alone. Standalone testing used 100% Hologic exams from three US centers, so that cohort does not establish all vendors or local configurations.

Clinical takeaway. Clinical role: Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.

Evidence takeaway. Evidence from the reviewed source record: FDA testing included a fully crossed multi-reader multi-case study of 240 combined DBT/2D mammograms with a prior, read with and without MammoScreen 3 by 23 MQSA-qualified and ABR-certified radiologists. Reader average AUC increased from 0.797 unaided to 0.871 aided; sensitivity increased from 0.706 to 0.793 and specificity from 0.815 to 0.836. Standalone mammogram-level performance used 7,544 exams from 4,429 patients at three US centers, with 1,053 positive and 6,420 negative cases, and reported AUROC 0.927 (95% CI 0.911-0.942), sensitivity 0.912 (95% CI 0.895-0.928), and specificity 0.727 (95% CI 0.715-0.740). Reader-study and standalone endpoints are distinct.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent reading and reporting aid for physicians interpreting screening mammograms on compatible full-field digital mammography and digital breast tomosynthesis systems, optionally using compatible prior examinations; outputs are adjunctive and must not be the sole basis for patient-management decisions.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Concurrent reading and reporting support that supplies finding marks, suspicion scores, lesion type and location, reporting-system content, and optional patient-management-worklist content while the interpreting physician remains the sole decision-maker.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Compatible current FFDM, DBT+FFDM, or DBT+2DSM examinations, with optional compatible prior FFDM or DBT+2DSM examination acquired 6 to 60 months before the current study; the packet specifies supported current/prior combinations.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Graphical marks for soft-tissue lesions or calcifications, a MammoScreen Score from 1 to 10 at finding, breast, and case levels, lesion characterization as mass/asymmetry, distortion, or calcifications, and location including quadrant, depth, and distance from the nipple; outputs can support DICOM viewing, preliminary reporting, and worklist content.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Screening mammography interpretation and reporting workflow; the FDA packet does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Physicians qualified to read mammograms; the FDA reader study used MQSA-qualified and ABR-certified radiologists.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Use requires compatible FFDM/DBT systems and only the packet's supported current/prior combinations. Outputs are complementary information, not a replacement for physician review or judgment, and patient-management decisions must not rely on the analysis alone. Standalone testing used 100% Hologic exams from three US centers, so that cohort does not establish all vendors or local configurations.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA testing included a fully crossed multi-reader multi-case study of 240 combined DBT/2D mammograms with a prior, read with and without MammoScreen 3 by 23 MQSA-qualified and ABR-certified radiologists. Reader average AUC increased from 0.797 unaided to 0.871 aided; sensitivity increased from 0.706 to 0.793 and specificity from 0.815 to 0.836. Standalone mammogram-level performance used 7,544 exams from 4,429 patients at three US centers, with 1,053 positive and 6,420 negative cases, and reported AUROC 0.927 (95% CI 0.911-0.942), sensitivity 0.912 (95% CI 0.895-0.928), and specificity 0.727 (95% CI 0.715-0.740). Reader-study and standalone endpoints are distinct.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA testing included a fully crossed multi-reader multi-case study of 240 combined DBT/2D mammograms with a prior, read with and without MammoScreen 3 by 23 MQSA-qualified and ABR-certified radiologists. Reader average AUC increased from 0.797 unaided to 0.871 aided; sensitivity increased from 0.706 to 0.793 and specificity from 0.815 to 0.836. Standalone mammogram-level performance used 7,544 exams from 4,429 patients at three US centers, with 1,053 positive and 6,420 negative cases, and reported AUROC 0.927 (95% CI 0.911-0.942), sensitivity 0.912 (95% CI 0.895-0.928), and specificity 0.727 (95% CI 0.715-0.740). Reader-study and standalone endpoints are distinct.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
0.912 (95% CI: 0.895-0.928) at the overall standalone mammogram-level endpoint
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA table supports this point estimate for 1,053 positive and 6,420 negative standalone cases; reader-assisted and standalone sensitivity endpoints must remain separate.

Reported specificity
0.727 (95% CI: 0.715-0.740) at the overall standalone mammogram-level endpoint
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA table supports this point estimate for the defined standalone cohort; it is distinct from AUROC and reader-study specificity.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MammoScreen® (3) regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested version3
  • Samplen=7544
  • Sites3
  • IndependenceIndependence not established

K240301

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240301. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible current FFDM, DBT+FFDM, or DBT+2DSM examinations, with optional compatible prior FFDM or DBT+2DSM examination acquired 6 to 60 months before the current study; the packet specifies supported current/prior combinations.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K240301: MammoScreen® (3)

  2. Routing

    Source context, not route validation: Results are accessible through a dedicated interface, can integrate into DICOM viewers using DICOM-SC and DICOM-SR, can populate a preliminary reporting-system report, and can place case scores in a patient-management worklist; specific PACS, RIS, EHR, versions, and local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K240301: MammoScreen® (3)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Graphical marks for soft-tissue lesions or calcifications, a MammoScreen Score from 1 to 10 at finding, breast, and case levels, lesion characterization as mass/asymmetry, distortion, or calcifications, and location including quadrant, depth, and distance from the nipple; outputs can support DICOM viewing, preliminary reporting, and worklist content.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K240301: MammoScreen® (3)

  5. Viewer/worklist/report

    Unresolved route: Graphical marks for soft-tissue lesions or calcifications, a MammoScreen Score from 1 to 10 at finding, breast, and case levels, lesion characterization as mass/asymmetry, distortion, or calcifications, and location including quadrant, depth, and distance from the nipple; outputs can support DICOM viewing, preliminary reporting, and worklist content.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K240301: MammoScreen® (3)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Results are accessible through a dedicated interface, can integrate into DICOM viewers using DICOM-SC and DICOM-SR, can populate a preliminary reporting-system report, and can place case scores in a patient-management worklist; specific PACS, RIS, EHR, versions, and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Supported acquisition environment

Supported hardware: Unspecified. Scanner manufacturers: Hologic/Lorad

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for MammoScreen® (3); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240301
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-08-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K240301 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240301: MammoScreen® (3)

    U.S. Food and Drug Administration - Published 2024-08-01 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MammoScreen® (3) model card (K240301)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240301

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Therapixel is now ISO/IEC 27001 certified

    Therapixel - Accessed 2026-10-25

    Scope: security

Research history

  1. K240301 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history